Skip to content
    RCUS
    Earnings call· Dec 2025(Q4 FY25)

    Arcus Biosciences Q4 FY25 earnings call RCUS

    Feb 25, 2026 Source

    Executive summary

    Arcus Biosciences Q4 FY25 — Casdatifan's Best-in-Class Profile and Frontline RCC Strategy

    Arcus Biosciences is advancing casdatifan as a best-in-class HIF-2 alpha inhibitor for clear cell RCC, demonstrating superior efficacy in late-line monotherapy and pursuing a TKI-free frontline strategy. The company is also developing an immunology portfolio with two programs expected to enter the clinic in late 2026 or early 2027. Arcus maintains a strong financial position, with cash and investments providing a runway into 2028, and anticipates several key data readouts and Phase III initiations in the coming year.

    Highlights

    5

    • Casdatifan monotherapy in late-line clear cell RCC achieved an unprecedented 45% ORR in the 100mg QD cohort, an increase from 35%.

    • Median PFS for casdatifan 100mg QD cohort reached 15.1 months, which is 2 to 3 times longer than belzutifan's 5.6 months in the same setting.

    • Cash and investments totaled $1 billion at the end of Q4 FY25, bolstered by a $288 million financing.

    • The company's cash runway is extended to fund operations until at least the second half of 2028.

    • The PEAK-1 Phase III study for casdatifan is actively enrolling and is targeted to complete enrollment by year-end 2026.

    Concerns

    3

    • The STAR-121 study will undergo a futility analysis in the coming months, with potential for discontinuation.

    • Current anti-PD-1 plus anti-CTLA-4 therapy in frontline RCC is associated with a relatively high primary progression rate of 20% to 25%.

    • Merck's LITESPARK-011 study data for belzutifan plus lenvatinib, to be presented at ASCO GU, may set a high competitive bar in the second-line setting.

    Guidance & targets

    5
    CategoryTargetConfidence
    GAAP Revenue
    $45 million to $55 million
    high materiality
    High
    Cash runway
    until at least the second half of 2028
    high materiality
    High
    PEAK-1 Phase III enrollment
    complete enrollment by year-end
    medium materiality
    High
    First frontline Phase III study for casdatifan
    initiate at the end of this year
    high materiality
    High
    Immunology programs clinic entry
    advance our 2 lead programs targeting inflammation and autoimmune disease into the clinic by early next year
    medium materiality
    Medium

    Operational metrics

    16
    Cash and investments balance
    $1 billionvs $841 million as of Q3 FY25
    Q4 FY25

    Cash and investments balance at the end of the fourth quarter.

    Financing proceeds
    $288 million
    November 2025

    Proceeds from financing in November that bolstered the cash position.

    GAAP Revenue
    $33 millionvs $26 million for Q3 FY25
    Q4 FY25

    GAAP revenue recognized for the fourth quarter, primarily driven by collaboration with Gilead.

    R&D expenses
    $121 millionvs $141 million in Q3 FY25
    Q4 FY25

    Research and development expenses for the fourth quarter.

    G&A expenses
    $26 millionvs $27 million for Q3 FY25
    Q4 FY25

    General and administrative expenses for the fourth quarter.

    Noncash stock-based compensation
    $15 millionvs $14 million for Q3 FY25
    Q4 FY25

    Total noncash stock-based compensation for the fourth quarter.

    Second entrant market share (oncology, 0 differentiation)
    42%
    historical

    Historical data for second entrants in a 2-player oncology market with no differentiation.

    Fast follower market share (oncology, with differentiation)
    up to 85%
    historical

    Oncology analogs have shown fast followers with differentiation can capture this much share.

    RCC drug market (major markets)
    $10 billionanticipated to grow to $13 billion by 2030
    annually today

    Size and projected growth of the RCC drug market in major markets.

    Belzutifan annual run rate sales
    nearly $1 billion
    annual run rate

    Annual run rate sales for the sole marketed HIF-2 alpha inhibitor, belzutifan.

    IO-experienced patient population
    approximately 21,000 patients
    today

    Patient population targeted by the PEAK-1 study, more than twice the third-line population.

    Primary progression rate (belzutifan monotherapy)
    35%
    Phase III trial

    Primary progression rate observed with belzutifan monotherapy in its Phase III trial.

    Primary progression rate (casdatifan + zim)
    9%
    first 23 of 30 patients

    Primary progression rate observed in the casdatifan plus zim cohort of ARC-20.

    Primary progression rate (ipi/nivo)
    20% to 25%
    current

    Relatively high rate of primary progression for anti-PD-1 plus anti-CTLA-4 therapy.

    Median PFS (ipi/nivo)
    about 12 months
    current

    Median PFS for IO-only regimens in clear cell RCC.

    IO/IO regimen preference
    3x morethan IO/TKI regimen
    market research

    Market research finding on preferred combination partner for CAS in the frontline.

    Industry KPIs

    2
    MetricValueDetails
    Peak long term sales guidance$5 billionUSD
    Clinical trial efficacy safety data45% ORR, 15.1 months median PFS

    Deals & partnerships

    2
    GileadCollaboration driving revenue

    Revenue is primarily driven by the collaboration with Gilead.

    AstraZenecaCollaboration for EVOLVE study

    Collaboration for the EVOLVE study, evaluating casdatifan plus forimtamig (an anti-PD-1 CTLA-4 bispecific).

    Risks & headwinds

    4
    Futility of STAR-121 studyNext couple of months

    Potential discontinuation

    Mitigation: Operational impact is minimal as study is largely enrolled; R&D expense decrease expected.

    Competitive landscape in HIF-2 alpha inhibitionNear-term (ASCO GU)

    Merck is slightly ahead; LITESPARK-011 data may set a high bar in second line.

    Mitigation: Confidence in casdatifan's best-in-class profile; PEAK-1 study designed to outperform and capture substantial share.

    Challenges in adjuvant setting for RCCLonger-term

    Lower priority due to market size, 12-month max treatment, and high safety bar.

    Mitigation: Focus on higher priority frontline and IO-experienced settings; continuous evaluation of adjuvant data.

    Potential safety signals for MRGPRX2 antagonistClinical development

    Liver function issues with high xenobiotic exposure

    Mitigation: Molecule designed for better potency and lower dosing to improve therapeutic index and avoid liver toxicity.

    What to watch in Q1 FY26

    5

    STAR-121 Futility Analysis Outcome

    Q1 FY26
    CurrentFutility analysis expected in next couple of months
    TargetDecision on discontinuation and impact on R&D spend

    Why it matters

    The outcome will impact R&D expenses and the company's clinical pipeline focus.

    The magnitude of this decrease will be in part determined by the results of the futility analysis for STAR-121, which will be conducted in the next couple of months.

    Q&A highlights

    8

    What IO/IO benchmarks are you using for the TKI-sparing frontline strategy, and what improvement are you targeting?

    Management cited ipi/nivo (CheckMate-214, COSMIC-313) as the primary benchmark, noting its 20-25% primary progression rate and ~12 months median PFS. They aim to demonstrate meaningful improvement, particularly in reducing primary progression, with early data from cas + anti-PD-1 showing potential for single-digit rates.

    “I think those numbers become very clear, simple lines to put in the sand where, obviously, we want to demonstrate meaningful improvement.”

    asked by Salim Syed · answered by Terry Rosen

    2 min read6 chapters

    Detailed Narrative

    01

    Casdatifan's Best-in-Class Profile and Efficacy

    Arcus Biosciences is positioning casdatifan as a best-in-class HIF-2 alpha inhibitor, citing its differentiated PK/PD profile and superior EPO production inhibition. Updated data from the ARC-20 study in late-line clear cell RCC showed a confirmed ORR of 45% for the 100mg QD cohort, an increase from 35% previously, and a median PFS of 15.1 months. This efficacy is noted as significantly higher than belzutifan's 5.6 months PFS in the same setting, achieved without the toxicities associated with TKIs.

    02

    Frontline RCC Strategy and TKI-Free Regimens

    The company's frontline strategy for RCC focuses on developing TKI-free casdatifan regimens, specifically combining casdatifan with anti-PD-1 and potentially anti-CTLA-4. This approach aims to improve upon the 20-25% primary progression rate and approximately 12-month median PFS of current IO-only therapies. Early data from the casdatifan plus zim (anti-PD-1) cohort showed a 9% primary progression rate, supporting the feasibility of a TKI-sparing backbone. Market research indicates a 3x preference for IO/IO regimens over IO/TKI for casdatifan combinations.

    03

    PEAK-1 Phase III Study Progress

    The PEAK-1 Phase III study, evaluating casdatifan plus cabozantinib versus cabozantinib alone in IO-experienced clear cell RCC, is actively enrolling. The study has a sole primary endpoint of PFS, designed for a relatively short time to readout. Management expects the upcoming LITESPARK-011 data for belzutifan plus lenvatinib to validate and de-risk the HIF-2 alpha class in earlier lines, thereby amplifying enthusiasm and driving PEAK-1 enrollment to completion by year-end 2026.

    04

    Immunology Portfolio Development

    Arcus is advancing an immunology portfolio, leveraging its small molecule capabilities to target validated mechanisms. Two lead programs, an MRGPRX2 antagonist and a TNF inhibitor, are expected to enter the clinic in late 2026 or early 2027. The MRGPRX2 antagonist targets chronic urticaria and atopic dermatitis, aiming for improved potency and pharmacokinetics over competitors. The TNF inhibitor is designed to selectively prevent TNF receptor 1 activation, potentially offering a safer alternative to existing anti-TNF antibodies.

    05

    Financial Performance and Outlook

    For Q4 FY25, Arcus reported $33 million in GAAP revenue, up from $26 million in Q3. R&D expenses were $121 million, down from $141 million in Q3. The company ended the quarter with $1 billion in cash and investments, significantly boosted by a $288 million financing in November. This financial position is projected to fund operations until at least the second half of 2028. Full-year 2026 GAAP revenue is guided to be between $45 million and $55 million, with operating expenses expected to decrease meaningfully.

    06

    Upcoming Milestones and Strategic Focus

    Key upcoming events include ASCO GU presentations for casdatifan monotherapy and LITESPARK-011 data. Later in 2026, the company plans to present updated data for the casdatifan plus cabozantinib cohort and new data from the casdatifan plus zim cohort of ARC-20. Arcus aims to initiate a second Phase III study for casdatifan in the frontline setting by year-end 2026, informed by ongoing ARC-20 combination cohorts. The company also expects its two lead immunology programs to enter the clinic by early 2027.

    AI-generated summary of the company’s earnings call. Not investment advice.